Cyclacel Pharmaceuticals, Inc. (CYCC,CYCCP) announced new data from an ongoing, multicenter, Phase 2 randomized trial of oral sapacitabine capsules, the Company's lead product candidate, in older patients with myelodysplastic syndromes (MDS) after treatment failure of front-line hypomethylating agents, such as azacitidine (Vidaza) and/or decitabine (Dacogen).
Median overall survival to date for all patients is 252 days or approximately 8.4 months. Data were presented as a poster during the 2012 American Society of Clinical Oncology or ASCO Annual Meeting being held June 1-5, 2012, in Chicago, Illinois.
At ASCO, the median overall survival for each arm was reported as follows: 240 days (approx. 8 months) for Arm G, 290 days (approx. 10 months) for Arm H, and 153 days (approx. 5 months) for Arm I. The median overall survival for all three arms is 252 days (approx. 8 months).
The company said that complete remissions (CRs) and major hematologic improvement (HI) in platelet counts or neutrophils, secondary efficacy endpoints in the study, were observed on all 3 dosing schedules as follows: 1 CR and 3 HI's in Arm G, 1 CR and 2 HI's in Arm H, and 2 CRs and 1 HI in Arm I. The thirty-day mortality from all causes is 5%. Forty-one percent of all patients received 4 or more cycles. More than 34% of the patients are still alive and longer follow-up is needed to assess 1-year survival and overall survival.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.